Biomea Fusion, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations, clinical-program updates, and capital-structure information for its common stock.
The company’s proxy materials cover annual meeting voting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. These filings frame Biomea’s disclosures around icovamenib, BMF-650, pipeline development, financing needs, governance, and public-company reporting obligations.
CVI Investments, Inc. and Heights Capital Management, Inc. filed an amended ownership report showing beneficial holdings of 7,847,232 Biomea Fusion common shares, or 9.9% of the class. The position consists entirely of shares issuable upon exercise of warrants, not currently outstanding stock.
The warrants are subject to a 9.99% beneficial ownership cap, limiting exercises so the reporting persons and their affiliates cannot exceed that level. Heights Capital Management acts as investment manager to CVI Investments and may be deemed to share voting and dispositive power, while both entities disclaim beneficial ownership beyond their pecuniary interest.
Blue Owl Capital Holdings LP filed a Schedule 13G reporting beneficial ownership in Biomea Fusion, Inc. common stock. The firm reports beneficial ownership of 4,451,219 shares of common stock issuable upon exercise of warrants, representing 5.92% of the class.
Blue Owl has shared voting and shared dispositive power over these 4,451,219 warrant shares and no sole voting or dispositive power. The ownership percentage is calculated using 70,703,639 shares of common stock outstanding as of October 31, 2025, increased by the warrant shares. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Biomea Fusion.
Rainer M. Erdtmann filed an amended Schedule 13G reporting beneficial ownership of 2,782,707 shares of Biomea Fusion, Inc. common stock, representing 3.9% of the class as of the measurement date. The holdings include directly owned shares, stock options exercisable within 60 days, and shares held by his children and two independent trusts.
The ownership percentage is based on 70,703,639 shares outstanding as of October 31, 2025, plus 690,677 option shares exercisable within 60 days after December 31, 2025. Erdtmann also notes he resigned on December 19, 2025 from Point Sur Investors’ general partner and is no longer deemed a beneficial owner of securities held by those entities.
Biomea Fusion, Inc. reported that it presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 and made the associated slide deck available on its website. The company also updated its broader corporate investor presentation, which it plans to use with investors, analysts and other third parties.
Both the conference presentation (Exhibit 99.1) and the corporate presentation (Exhibit 99.2) are included as exhibits and are being furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other securities filings. The company highlights that these materials contain forward-looking statements about its product candidates, clinical programs, regulatory plans and anticipated trial data, and emphasizes that actual results may differ due to clinical, regulatory and operational risks described in its SEC reports.
Biomea Fusion, Inc. executive and director Rainer M. Erdtmann reported buying 30,000 shares of Biomea Fusion common stock on 12/11/2025 at a weighted-average price of $1.4333 per share. After this transaction, he directly owns 723,027 shares.
Erdtmann also reports indirect holdings, including 19,400 shares held by a daughter, 20,000 shares held by a son, 20,000 shares held by another daughter, and additional shares held in two independent trusts and two Point Sur investment entities where he has voting or dispositive power but disclaims beneficial ownership beyond any pecuniary interest. He serves as President, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer, and a director of Biomea Fusion. The 30,000-share purchase was executed in multiple trades between $1.42 and $1.46 per share.
Biomea Fusion, Inc. (BMEA) filed its Q3 2025 report, highlighting reduced operating spend and liquidity pressure. The company reported a Q3 net loss of $16.4 million and basic/diluted loss per share of $0.27. Operating expenses fell to $20.8 million, driven by lower research and development costs, while interest and other income was $4.4 million.
Cash, cash equivalents and restricted cash were $47.0 million as of September 30, 2025. The filing states there is substantial doubt about the company’s ability to continue as a going concern, absent additional financing. A $2.2 million non‑cash impairment was recorded after ceasing laboratory use for R&D. A warrant liability of $17.9 million reflects the fair value of common warrants issued in June 2025.
To bolster liquidity, the company completed public offerings in June and on October 6, 2025, with the October transaction generating approximately $25.0 million in gross proceeds. Shares outstanding were 59,508,518 as of September 30, 2025 and 70,703,639 as of October 31, 2025. Clinical programs continue, including Phase II trials of icovamenib in diabetes and the IND‑cleared BMF‑650 with an ongoing Phase I trial.
Biomea Fusion, Inc. (BMEA) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 to a current report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The company notes that the information provided under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act.
This amendment reports that a Cormorant investment group and director Bihua Chen together hold a meaningful minority stake in Biomea Fusion, Inc. The filing discloses group-wide shared voting and dispositive power over 3,570,872 shares, equal to 5.15% of common stock, and that Ms. Chen separately holds or controls an additional 110,792 shares and options exercisable within 60 days, bringing her aggregate economic interest to 3,681,664 shares or 5.31% of the company.
The percentage calculations use a post-offering share count of 69,322,377 common shares as stated in the filing materials. The filing also notes there were no transactions in the issuer's securities by the reporting persons during the sixty-day period before this statement, and it updates identity, citizenship, and source-of-funds information for the reporting entities.
Biomea Fusion, Inc. filed an Form 8-K reporting several exhibits tied to a securities offering and related legal opinions. The filing lists an Underwriting Agreement dated October 6, 2025 naming Jefferies LLC as representative, forms for a Pre-Funded Warrant and a Common Stock Warrant, and an opinion and consent from Goodwin Procter LLP (consent included in Exhibit 5.1). The company also attached two press releases dated October 6, 2025 and October 7, 2025 and an interactive XBRL cover page. The filing is signed by the company on October 7, 2025.
Biomea Fusion, Inc. (BMEA) is offering common shares together with accompanying common stock warrants or pre-funded warrants at a combined public offering price of $2.05 per unit, with total proceeds of approximately $24.999M without option exercise and up to $28.75M if the underwriters’ option is fully exercised. Each common stock warrant has an initial exercise price of $2.50, is exercisable immediately and expires three years after issuance. Pre-funded warrants have an exercise price of $0.0001 and are exercisable on a cashless basis subject to ownership limitations (default thresholds of 4.99 or 9.99, expandable to 19.99 with notice).
Proceeds are intended to fund the Phase IIb development of Icovamenib in type 2 diabetes and clinical development of the oral GLP-1 receptor agonist candidate BMF-650, plus general corporate purposes. The prospectus notes limited liquidity for the warrants (no listing expected) and lock-up agreements restricting certain insiders for 60 days. Tax and transfer mechanics for non-U.S. holders and exercise limitations are described; holders have no stockholder rights until exercise.